Equities research analysts expect BioLineRx Ltd. (NASDAQ:BLRX) to post ($0.05) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for BioLineRx’s earnings. BioLineRx reported earnings per share of ($0.08) during the same quarter last year, which would suggest a positive year over year growth rate of 37.5%. The business is scheduled to announce its next earnings report on Tuesday, November 28th.
According to Zacks, analysts expect that BioLineRx will report full year earnings of ($0.24) per share for the current year, with EPS estimates ranging from ($0.24) to ($0.23). For the next year, analysts anticipate that the company will report earnings of ($0.23) per share, with EPS estimates ranging from ($0.24) to ($0.22). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow BioLineRx.
BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05).
A number of research analysts recently issued reports on BLRX shares. Zacks Investment Research lowered BioLineRx from a “buy” rating to a “hold” rating in a research report on Friday, May 26th. Maxim Group set a $3.00 price objective on BioLineRx and gave the company a “buy” rating in a research report on Thursday, May 25th. HC Wainwright set a $4.00 price objective on BioLineRx and gave the company a “buy” rating in a research report on Wednesday, August 9th. Roth Capital started coverage on BioLineRx in a research report on Thursday, August 3rd. They set a “buy” rating and a $3.00 price objective for the company. Finally, ValuEngine upgraded BioLineRx from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. BioLineRx presently has a consensus rating of “Buy” and a consensus price target of $2.59.
A number of institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC raised its stake in BioLineRx by 443.4% during the 1st quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 86,481 shares in the last quarter. Benchmark Capital Advisors raised its stake in BioLineRx by 227.3% during the 1st quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock valued at $138,000 after acquiring an additional 100,000 shares in the last quarter. Renaissance Technologies LLC bought a new stake in BioLineRx during the 1st quarter valued at $126,000. KCG Holdings Inc. raised its stake in BioLineRx by 715.9% during the 1st quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 153,687 shares in the last quarter. Finally, Sabby Management LLC bought a new stake in BioLineRx during the 1st quarter valued at $3,018,000. 32.27% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Analysts Expect BioLineRx Ltd. (BLRX) Will Announce Earnings of -$0.05 Per Share” was reported by Markets Daily and is the property of of Markets Daily. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/09/13/analysts-expect-biolinerx-ltd-blrx-will-announce-earnings-of-0-05-per-share.html.
Shares of BioLineRx (BLRX) opened at 1.04 on Wednesday. The stock’s 50 day moving average price is $1.07 and its 200 day moving average price is $0.97. BioLineRx has a 1-year low of $0.80 and a 1-year high of $1.42. The stock’s market cap is $99.44 million.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.